2025, Number 1
<< Back Next >>
Rev Hematol Mex 2025; 26 (1)
Efficacy of the CALGB 10403 regimen on medicinal residual postinduction. Experience of a Latin American center
Tejeda RM, Mayo ML
Language: Spanish
References: 4
Page: 1-3
PDF size: 230.82 Kb.
Text Extraction
No abstract.
REFERENCES
Stock W, Luger SM, Advani AS, Yin J, et al. A pediatricregimen for older adolescents and young adults withacute lymphoblastic leukemia: results of CALGB 10403.Blood 2019; 133 (14): 1548-59. https://doi.org.10.1182/blood-2018-10-881961
Rangel-Patiño J, Lee-Tsai YL, Urbalejo-Ceniceros VI, Luna-Perez MEM, et al. A modified CALGB 10403 in adolescentsand young adults with acute lymphoblastic leukemia inCentral America. Blood Adv 2023; 7 (18): 5202-9. http://dx.doi.org/10.1182/bloodadvances.2023009754
Crespo-Solis E, Espinosa-Bautista K, Alvarado-Ibarra M,Rozen-Fuller E, et al. Survival analysis of adult patients withALL in Mexico City: first report from the Acute LeukemiaWorkgroup (ALWG) (GTLA). Cancer Med 2018; 7 (6): 2423-33. http://dx.doi.org/10.1002/cam4.1513
Berry DA, Zhou S, Higley H, Mukundan L, et al. Associationof minimal residual disease with clinical outcomein pediatric and adult acute lymphoblastic leukemia: Ameta-analysis. JAMA Oncol 2017; 3 (7): e170580. http://dx.doi.org/10.1001/jamaoncol.2017.0580
Full text